Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules

Anil Vachani, Zane Hammoud, Steven Springmeyer, Neri Cohen, Dao Nguyen, Christina Williamson, Sandra Starnes, Stephen Hunsucker, Scott Law, Xiao-Jun Li, Alexander Porter, Paul Kearney, Anil Vachani, Zane Hammoud, Steven Springmeyer, Neri Cohen, Dao Nguyen, Christina Williamson, Sandra Starnes, Stephen Hunsucker, Scott Law, Xiao-Jun Li, Alexander Porter, Paul Kearney

Abstract

Evaluation of indeterminate pulmonary nodules is a complex challenge. Most are benign but frequently undergo invasive and costly procedures to rule out malignancy. A plasma protein classifier was developed that identifies likely benign nodules that can be triaged to CT surveillance to avoid unnecessary invasive procedures. The clinical utility of this classifier was assessed in a prospective-retrospective analysis of a study enrolling 475 patients with nodules 8-30 mm in diameter who had an invasive procedure to confirm diagnosis at 12 sites. Using this classifier, 32.0 % (CI 19.5-46.7) of surgeries and 31.8 % (CI 20.9-44.4) of invasive procedures (biopsy and/or surgery) on benign nodules could have been avoided. Patients with malignancy triaged to CT surveillance by the classifier would have been 24.0 % (CI 19.2-29.4). This rate is similar to that described in clinical practices (24.5 % CI 16.2-34.4). This study demonstrates the clinical utility of a non-invasive blood test for pulmonary nodules.

Trial registration: ClinicalTrials.gov NCT01752101.

Keywords: Biomarker; Clinical utility; Lung cancer; Lung nodule; Prospective; Xpresys lung.

Figures

Fig. 1
Fig. 1
Flowchart of subjects included in clinical utility analyses along with categorization of subjects by procedure, outcome and classifier report. ‘LB’ and ‘IND’ represent a classifier ‘Likely Benign’ and ‘Indeterminate’ report, respectively. Dx indicates diagnostic, Non-Dx is a non-diagnostic procedure, and Dx Biopsy includes patients with a biopsy only and those that had a diagnostic biopsy followed by surgery
Fig. 2
Fig. 2
The incorporation of the classifier into the ACCP guidelines for lung nodule management. Newly identified lung nodules between 8 and 30 mm in diameter are assessed using the plasma protein classifier. The classifier results are integrated into the physician’s assessment of cancer risk

References

    1. Ost D, Fein AM, Feinsilver SH. The solitary pulmonary nodule. N Engl J Med. 2003;348(25):2535–2542. doi: 10.1056/NEJMcp012290.
    1. Gould MK, Ananth L, Barnett PG. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest. 2007;131:383–388. doi: 10.1378/chest.06-1261.
    1. Tanner NT, Aggarwal J, Gould MK, Kearney P, Diette G, Vachani A, Fang KC, Silvestri GA. Management of pulmonary nodules by community pulmonologists: a multicenter observational study. Chest. 2015
    1. Vachani A, Tanner NT, Diette GB, Aggarwal J, Mathews C, Goss T, Kearney P, Fang K, Silvestri G. A Markov model derived to quantify drivers of decision making in the evaluation of patients with pulmonary nodules. Am J Repir Crit Care Med. 2014;189:A2259.
    1. Jensen T, Chin J, Ashby L. Hermansen J, Hutter JD (2015) Decision memo for screening for lung cancer with low dose computed tomography (LDCT). . Accessed 8 June 2015
    1. Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2015;5(207):207ra142.
    1. Spira A for the AEGIS Study Team. Silvestri GA, Vachani A, Whitney D, Elashoff M, Smith PK, Ferguson JS, Parsons E, Mitra N, Brody J, Lenburg ME. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med. 2015;365:395–409.
    1. Vachani A, Pass H, Rom WN, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. J Thorac Oncol. 2015;10:629–637. doi: 10.1097/JTO.0000000000000447.
    1. Li XJ, Lee LW, Hayward C, et al. An integrated quantification method to increase the precision, robustness, and resolution of protein measurement in human plasma samples. Clin Proteomics. 2015;12:1–17. doi: 10.1186/1559-0275-12-3.
    1. R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
    1. Haddow J, Palomaki G. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, editors. Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. Oxford: Oxford University Press; 2003. pp. 217–233.
    1. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(38):1–7.
    1. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e93S–e120S. doi: 10.1378/chest.12-2351.
    1. Simon R, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446–1452. doi: 10.1093/jnci/djp335.
    1. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88(20):1456–1466. doi: 10.1093/jnci/88.20.1456.
    1. Aberle DR, Adams AM, Berg CD, et al. Reduced lung cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. doi: 10.1056/NEJMoa1102873.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir